

**North Central Cancer Treatment Group**

N0877: Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Status Change – August 10, 2009

**NOTICE OF STATUS CHANGE**

Accrual to dose level 0 has been met. Therefore, this study is temporarily closed to patient accrual for safety assessment per study design effective Monday, August 10, 2009.

**Please retain this notice with the protocol.**